Celldex Therapeutics, Inc. 8-K

What Happened

• Celldex Therapeutics, Inc. (CLDX) filed an 8-K reporting that Senior Vice President and Chief Financial Officer Sam Martin notified the company on July 10, 2026 that he plans to retire effective on or about March 31, 2027. Mr. Martin joined Celldex in April 2009 and has served as CFO since July 2017. The company has initiated a search for a new Chief Financial Officer. Mr. Martin intends to continue serving as CFO through March 31, 2027 or until his successor assumes the role.

Key Details

• Sam Martin notification date: July 10, 2026.
• Planned retirement effective: on or about March 31, 2027 (or earlier if successor starts sooner).
• Tenure: with Celldex since April 2009; CFO since July 2017.
• Company action: formal search for a successor underway to ensure a smooth transition.

Why It Matters

• A planned CFO retirement is a material leadership change for investors because the CFO oversees financial reporting, budgeting, and investor communications. The announced timeline and Martin’s commitment to remain through March 31, 2027 (or until a successor is in place) reduces the risk of an immediate disruption. Investors should watch for announcements about the CFO search, naming of a successor, and any related changes to financial strategy or guidance.